8-K: BioAtla Receives Nasdaq Notice Regarding Minimum Bid Price Deficiency

BioAtla, Inc. received a notification from Nasdaq stating that it is not in compliance with the minimum bid price requirement, giving the company until August 5, 2025, to regain compliance.

Summary

• BioAtla, Inc. received a notice from Nasdaq on February 6, 2025, stating that it doesn't meet the minimum bid price requirement of $1.00 per share for its common stock.
• The company has 180 calendar days, until August 5, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2).
• If compliance isn't achieved within the initial 180-day period, an additional 180-day compliance period may be granted if BioAtla transfers to The Nasdaq Capital Market and meets other listing requirements.
• Compliance can be achieved by maintaining a minimum bid price of $1.00 for at least ten consecutive business days during the compliance period.
• Failure to regain compliance could result in the delisting of BioAtla's common stock from Nasdaq.
• BioAtla intends to monitor its stock's bid price and consider options to regain compliance, but there's no guarantee it will succeed.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the risk of delisting, but the company has time to regain compliance. The intention to monitor and consider options is a positive sign, but the lack of guarantee tempers the outlook.

Positives

• BioAtla has been granted a 180-day period to regain compliance with Nasdaq's minimum bid price rule.
• The company may be eligible for an additional 180-day compliance period by transferring to The Nasdaq Capital Market.
• BioAtla intends to actively monitor its stock price and explore options to regain compliance.

Negatives

• BioAtla is currently not in compliance with Nasdaq's minimum bid price requirement.
• Failure to regain compliance could lead to the delisting of the company's common stock.
• There is no guarantee that BioAtla will be able to regain compliance with the Rule.

Risks

• The primary risk is the potential delisting of BioAtla's common stock from Nasdaq if the minimum bid price isn't maintained.
• Delisting could negatively impact the company's stock price and investor confidence.
• The company's ability to raise capital could be hindered if it is delisted.

Future Outlook

BioAtla intends to monitor the bid price of its listed securities and may consider available options to regain compliance with the Rule; however, there is no assurance that the Company will be able to regain compliance with the Rule.

Management Comments

• BioAtla intends to monitor the bid price of the Company's listed securities and may, if appropriate, consider available options to regain compliance with the Rule.

Industry Context

Many biotech companies, especially those in the development stage, can face challenges in maintaining share price compliance, particularly during periods of market volatility or when clinical trial results are pending. This situation is not uncommon in the biotech industry.

Comparison to Industry Standards

• Other biotech companies that have faced similar Nasdaq compliance issues include companies like XOMA Corporation and Diffusion Pharmaceuticals, which have also received deficiency notices for failing to meet minimum bid price requirements.
• These companies often implement strategies such as reverse stock splits or focusing on positive clinical trial data releases to boost investor confidence and increase share price.
• Compared to industry averages, BioAtla's situation is not unique, but the company's ability to successfully navigate this challenge will depend on its specific pipeline progress and market conditions.

Stakeholder Impact

• Shareholders may experience a decline in stock value if the company is delisted.
• Employees may face uncertainty due to the potential impact on the company's operations.
• The company's ability to raise capital could be affected, impacting future growth and development.

Next Steps

• BioAtla will monitor its stock price.
• BioAtla may consider options to regain compliance with Nasdaq listing rules.
• BioAtla must achieve compliance by August 5, 2025, or potentially face delisting.

Key Dates